In 1990-1992, the Marketscan(SM) database included medical and pharmacy claims for approximately 700,000 individuals whose health insurance was provided by large corporations throughout the United States. Outcomes for 1242 patients treated with either fluoxetine (SSRI) or with a TCA / HCA for major depressive disorder (MDD) were discussed in Croghan et al. (1996) and Obenchain et al. (1997). All 1242 patients were continuously enrolled for at least 4 months prior to their initial antidepressant prescription and for the following 12 months.
A data frame of 3 variables on 1242 patients; no NAs.
stable = 1 indicates that the patient remained on his/her initial antidepressant medication for at least six consecutive months.
cost is the Marketscan(SM) 12 month total annual charge for a patient.
Treatment indicator variable; fluox = 1 indicates receipt of fluoxetine 20 mg/d by 799 patients. fluox = 0 implies receipt of either a tricyclic (TCA) or a heterocyclic (HCA) by 443 patients.
This dataset contains measures of cost and efffectiveness for 799 patients treated with fluoxetine (a Selective Serotonin Reuptake Inhibitor or SSRI), 104 patients treated with a first generation tricyclic, TCA (amitriptyline or imipramine), 250 patients treated with a second generation TCA (desipramine or nortriptyline), and 89 patients treated with trazodone (a heterocyclic, HCA).
Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Working paper, Eli Lilly and Company, 1996. (Presented in part at the Association for Health Services Research meeting, Chicago, June 9, 1995.)
Obenchain RL, Melfi CA, Croghan TW, Buesching DP. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. PharmacoEconomics 1997; 17: 1200–1206.
Sclar DA, Robison LM, Skaer TL, Legg RF, Nemec NL, Galin RS, Hugher TE, Buesching DP. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16: 715–730.
Loading required package: lattice Incremental Cost-Effectiveness (ICE) Lambda Scaling Statistics Specified Value of Lambda = 1 Cost and Effe Differences are both expressed in cost units Effectiveness variable Name = stable Cost variable Name = cost Treatment factor Name = fluox New treatment level is = 1 and Standard level is = 0 Observed Treatment Diff = 0.117 Std. Error of Trtm Diff = 0.028 Observed Cost Difference = -192.935 Std. Error of Cost Diff = 1003.158 Observed ICE Ratio = -1647.861 Statistical Shadow Price = 36416.684 Power-of-Ten Shadow Price= 10000
Add the following code to your website.
For more information on customizing the embed code, read Embedding Snippets.